475838 | Mifepristone - CAS 84371-65-3 - Calbiochem

475838
No pudo obtenerse el precio
Minimum Quantity needs to be mulitiple of
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar Disponibilidad a confirmar
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    Remaining : Will advise
      Se avisará
      Ver precios y disponibilidad
         CompararClick To Print This Page

      Overview

      Replacement Information

      Tabla espec. clave

      Fórmula empírica Nº CAS
      C₂₉H₃₅NO₂84371-65-3

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      475838-50MG
      Comprobando disponibilidad...
      Disponibilidad a confirmar Disponibilidad a confirmar
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        Remaining : Will advise
          Se avisará

          50 mg
          Recuperando precio...
          No pudo obtenerse el precio
          Minimum Quantity needs to be mulitiple of
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Descripción
          Visión de conjunto A cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Inhibits P-glycoprotein (P-gp) function and down-modulates P-gp mediated drug resistance. Displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Regulates the expression of Fas and FasL in mouse endometrium and TRAIL in prostate cancer cells. As an antioxidant, it offers neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
          Número de catálogo 475838
          Marca de familia Calbiochem®
          Sinónimos (11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
          Referencias bibliográficas
          Referencias bibliográficas McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
          Información del producto
          Número de CAS 84371-65-3
          ATP Competitivo N
          Formulario Yellow solid
          Fórmula Hill C₂₉H₃₅NO₂
          Fórmula química C₂₉H₃₅NO₂
          Molar Mass 429.6
          Reversible N
          Imagen fórmula estructural
          Aplicaciones
          Información biológica
          Objetivo principal Progesterone and glucocorticoid receptors
          Pureza ≥99% by titration
          Información fisicoquímica
          Permeabilidad celular Y
          Contaminantes Steroid substances: ≤0.1%
          Solubilidad EtOH
          Dimensiones
          Información de materiales
          Información toxicológica
          Información de seguridad según el GHS
          RTECS KG2955000
          Información de seguridad
          Frase R R: 60-61


          Frase S S: 22-36/37/39-45



          Declaraciones de uso del producto
          Información de almacenamiento y transporte
          Código de envío Ambient Temperature Only
          Toxicidad Carcinogenic / Teratogenic
          Almacenamiento +2°C to +8°C
          Proteger de la luz Protect from light
          No congelar No
          Instrucciones especiales Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Información sobre embalaje
          Envasado en atmósfera inerte Packaged under inert gas
          Información de transporte
          Información complementaria
          Especificaciones

          Documentation

          Ficha datos de seguridad (MSDS)

          Idiomas
          Argentina Australia Belgie
          Belgien Belgique Brasil
          Canadian English Canadian-French Ceská Rep
          Chile China Colombia
          Cyprus Danmark Deutschland
          Eesti Ellas English
          España France Hrvatska 
          Iceland India Indonesia
          Italia Korea Latvija
          Lietuva Magyarország Malta
          México Nederland  Norge
          Peru Polska Portugal
          Schweiz Slovenija Slovensko
          Srpski Standard EU English Suomi
          Sverige Taiwan Thailand
          Türkiye US English United Kingdom
          Éire Österreich България
          Россия

          Certificados de análisis

          CargoNúmero de lote
          475838

          Referencias bibliográficas

          Visión general referencias
          McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revisión 28-April-2009 RFH
          Sinónimos (11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
          Descripción A cell-permeable, synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Reported to inhibit P-glycoprotein (P-gp) function and down-modulate P-gp mediated drug resistance. Also displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Shown to regulate the expression of Fas and FasL in mouse endometrium and of TRAIL in prostate cancer cells. As an antioxidant, it is reported to offer neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
          Formulario Yellow solid
          Gas inerte (Sí/No) Packaged under inert gas
          Número de CAS 84371-65-3
          RTECS KG2955000
          Masa molar 429.6
          Fórmula química C₂₉H₃₅NO₂
          Fórmula estructural
          Pureza ≥99% by titration
          Contaminantes Steroid substances: ≤0.1%
          Solubilidad Ethanol (10 mg/ml)
          Almacenamiento +2°C to +8°C
          Protect from light
          Do Not Freeze No
          Special Instructions Following reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicidad Carcinogenic / Teratogenic
          Índice Merck EE.UU. 14, 6186
          Referencias bibliográficas McCullers, D.L., et al. 2002. Neuroscience 109, 219.
          Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
          Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
          Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
          Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
          Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
          Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
          Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
          Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.